RecruitingMajor Depressive Disorder

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Eligible age

18–65 yrs

Accepts

All genders

Locations

18 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

Sponsor: Axsome Therapeutics, Inc.

You may qualify if…

✓ Currently meets DSM-5 criteria for diagnosis of MDD without psychotic features
✓ Current major depressive episode of at least 4 weeks in duration

You may not qualify if…

✕ Previously participated in another clinical study of AXS-05; received any investigational drug or device treatment within 30 days of (Screening) Visit 1, or has been prescribed Auvelity.
✕ Unable to comply with study procedures
✕ Medically inappropriate for study participation in the opinion of the investigator